IMR Press / FBL / Special Issues / 1395668164247212034

Cutting Edge Research in Hepatocellular Carcinoma

Submission deadline: 30 April 2022
Special Issue Editor
Cheng-Maw Ho, MD
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
Interests: Acute liver failure; Liver regeneration; Liver cancer; Cell therapy; Liver transplantation; Minimally invasive liver surgery
Special Issue Information

Dear Colleagues,

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Multiple lines of research ranging from epidemiology, carcinogenesis, diagnostics, and therapeutics (including surgery and liver transplantation) had been actively in progress, to reduce the disease burden and to achieve primary, secondary, and tertiary prevention of HCC. Recent advances in immunotherapy further improve the prognosis of advanced HCC. This special issue welcomes articles in all areas related to HCC, either clinical, translational, or basic research in nature. Topics of cell therapy with sound scientific evidence or personalized medicine are especially welcome. Because liver reserve is a key factor limiting the therapeutic option of HCC, studies related to this (for example, liver fibrosis, cirrhosis, liver failure, and regeneration) are also considered. Other areas can include viral or metabolic liver diseases which predispose to liver cirrhosis and HCC development. Articles that present cell line studies should be accompanied with in vivo validation. Review articles can be extensive or focused analyses. I hope to receive your excellent work included in this special issue and contribute to literature in the field of HCC significantly.

Sincerely,

Dr. Cheng-Maw Ho

Guest Editor

Keywords
Hepatocellular carcinoma
Liver cancer
Treatment
Prognosis
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Open Access Original Research
Gene Signature and Prognostic Value of Ubiquitin-Specific Proteases Members in Hepatocellular Carcinoma and Explored the Immunological Role of USP36
Weijie Sun, Jiapei Shen, Jiaying Liu, Kexing Han, ... Yufeng Gao
Front. Biosci. (Landmark Ed) 2022, 27(6), 190; https://doi.org/10.31083/j.fbl2706190
(This article belongs to the Special Issue Cutting Edge Research in Hepatocellular Carcinoma)
13
Download
40
Views
Back to top